Advances in the Immunotherapy of Metastatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 5 June 2026 | Viewed by 973
Special Issue Editor
Special Issue Information
Dear Colleagues,
Metastatic cancer remains a difficult challenge in oncology, with traditional therapies often providing poor prognoses and very limited long-term benefits. However, the emergence of immunotherapy has radically transformed the management of metastatic cancers, with immune checkpoint inhibitors (ICIs) demonstrating remarkable and durable responses in multiple malignancies, including melanoma, non-small cell lung cancer, and renal cell carcinoma. Beyond ICIs, novel approaches such as adoptive cell therapies (CAR-T, TCR-T, and TIL therapies), cancer vaccines, oncolytic viruses, and bispecific antibodies are expanding the therapeutic armamentarium. Additionally, combination strategies integrating immunotherapy with chemotherapy, radiotherapy, or targeted agents are being actively explored to enhance efficacy and offer new hope for patients with advanced disease. Despite these successes, significant challenges remain, including primary and acquired resistance, immune-related adverse events, and the need for predictive biomarkers to optimize patient selection. This Special Issue explores the latest advancements in immunotherapy for metastatic cancer, covering mechanistic insights, preclinical and clinical studies, biomarker discovery, and emerging resistance mechanisms.
Dr. Gianluca Tomasello
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metastatic cancer
- immunotherapy
- immune checkpoint inhibitors
- CAR-T cells
- tumor microenvironment
- immune-related adverse events
- biomarkers
- combination therapy
- resistance mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
